Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Egetis Therapeutics AB ( (SE:EGTX) ).
Egetis Therapeutics held its Annual General Meeting in Stockholm on April 14, 2026, where shareholders approved all proposals, including adoption of the 2025 financial statements and discharge of the board and CEO from liability. The meeting re-elected four directors, appointed two new board members, confirmed Mats Blom as chairman, set a revised remuneration structure totaling SEK 5,039,999 through 2027, and appointed PwC with Niclas Bergenmo as auditor.
Shareholders also approved updated nomination committee instructions, executive remuneration guidelines, and the 2025 remuneration report, reinforcing the company’s governance framework. The AGM authorized new long-term share-based incentive programs for board members, management, and key staff, and granted the board a mandate to issue new shares, convertibles, and warrants, enhancing Egetis’s flexibility to retain talent and finance future growth initiatives.
More about Egetis Therapeutics AB
Egetis Therapeutics AB is a Sweden-based pharmaceutical company listed on Nasdaq Stockholm under the ticker EGTX. The company focuses on developing and commercializing therapies, with an emphasis on specialty and rare disease treatments, targeting both domestic and international healthcare markets.
Average Trading Volume: 809,966
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.37B
Learn more about EGTX stock on TipRanks’ Stock Analysis page.